PDCD1 and melanoma: Different ICIs, including programmed cell death protein-1 (PD-1)-blocking monoclonal antibodies (mAbs) and programmed death-ligand 1 (PD-L1)-targeted mAbs, have been approved to treat multiple types of cancers, including melanoma, lung cancer, and head and neck cancer 6-8.